Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 114 Results
NPC Releases Updated Guiding Practices to Improve Patient-Centricity in Value Assessments
The Guiding Practices include 33 specific recommendations to ensure value assessments account for the full value pharmaceuticals provide to patients and society
Guiding Practices for Patient-Centered Value Assessment (2024)
NPC has updated its Guiding Practices for Patient-Centered Value Assessment. This update of NPC's guiding practices for US value assessment will help inform the growing importance of this tool to…
ICER’s UPI Report: Unsupported Policy Information
The 2023 iteration of ICER's Unsupported Price Increase report is misguided at best and harmful to patients and society at worst. NPC outlines why the report should not be used to determine policy or…
NPC’s John O’Brien Talks IRA, Drug Pricing, Patient Costs & Access on The Real Chemistry Podcast
In the latest episode of The Real Chemistry Podcast, NPC President and CEO John M. O'Brien spoke with Real Chemistry’s Founder and Chairman, Jim Weiss, on pressing health policy issues.
NPC Evaluates ICER’s Revised 2023 Value Assessment Framework: A Missed Opportunity for Patients and the Field
The Institute for Clinical and Economic Review (ICER) released its revised value assessment framework. NPC outlines key concerns about the framework and the impact on both patients and those who…
NPC Comments on Proposed Changes for ICER Value Assessment Framework
NPC's comments highlight key concerns related to proposed changes to ICER's 2023 Value Assessment Framework.
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
Study shows the impact of a more holistic approach to assessing value and how it can help address gaps within conventional value assessment.
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and…
Making Our Health Care System More Supportive and Inclusive for Caregivers
NPC President and CEO John M. O'Brien writes about how we can better incorporate the needs of caregivers into our health care system and provide them the support they…
Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness
This paper focuses on recognizing methodological flaws in RWE studies so that researchers can avoid these flaws by identifying them ahead of time – not just after a study is complete.
Avoiding Methodological Faults in Real-World Evidence
Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…
Celebrating the Use of Medicines in Keeping People Healthy
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
Chairman’s Blog: Let Data and Research Guide the Pricing and Access Policy Debate
NPC Board Chair and BMS SVP Michael Ryan reflects on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about what it takes to bring…
A Perfect Storm: How the Public and Private Sectors Came Together to Save the World From COVID
Health care policy experts gathered for a panel discussion, “If the NIH Funds the Research, Should There Be a 'Government Discount?” focused on key questions regarding government funding for…
Forging a Path Toward a More Stable and Patient-Centric Health System in 2021
In his commentary for Chain Drug Review, NPC Interim President and CEO Dr. Robert Dubois explores the steps we can take to improve our current health care system in the wake of the COVID-19 pandemic.
What’s In Your RWE Evaluation Toolbox?
Real-world evidence (RWE) – information collected from everyday health care experiences – is growing in availability, and many health care decision-makers are interested in understanding and using…
Online Tools to Synthesize Real-World Evidence of Comparative Effectiveness Research to Enhance Formulary Decision Making
The authors describe and compare the features and characteristics of five tools to evaluate real-world evidence studies and add clarity on what the tools provide.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…